Europe
Upon the closing of the divestment, Grünenthal will make an upfront, non-contingent payment to AstraZeneca of $320 million.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 1, 2020.
Another clinical study could confirm the 90% efficacy data that stemmed from accidental use of a half-dose in an arm of its Phase III trial.
As the U.S. went into its Thanksgiving holiday week, clinical trial news was quieter than usual, although there was a lot of important news on the COVID-19 vaccine front. Here’s a look.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Even companies with otherwise promising pipelines or successful products on the market sometimes face clinical trial failures. Two such companies had disappointing clinical trial announcements today.
Find out which biopharma companies are raking in cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
To support its long-term goals, the Swiss pharma giant is initiating a share-buyback program of up to $2.5 billion that is expected to be carried out over the next few months.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
PRESS RELEASES